Search

Your search keyword '"Lopez-Pousa, Antonio"' showing total 208 results
Start Over Author "Lopez-Pousa, Antonio"
208 results on '"Lopez-Pousa, Antonio"'

2. Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor

Author

Carrillo-García, Jaime, Hindi, Nadia, Conceicao, Magda, Sala, María Ángeles, Ugalde, Aitziber, López-Pousa, Antonio, Bagué, Silvia, Sevilla, Isabel, Vicioso, Luis, Ramos, Rafael, Martínez-Trufero, Javier, Gómez Mateo, M<ce:sup loc='post">a</ce:sup> Carmen, Cruz, Josefina, Hernández-León, Carmen Nieves, Redondo, Andrés, Mendiola, Marta, García, Jerónimo Martínez, Hernández, José Emilio, Álvarez, Rosa, Agra, Carolina, de Juan-Ferré, Ana, Valverde, Claudia, Cano, Juana María, Sande, Luis Miguel de, Pérez-Fidalgo, José A., Lavernia, Javier, Marcilla, David, Gutiérrez, Antonio, Moura, David S., and Martín-Broto, Javier

Published
2024
Full Text
View/download PDF

3. Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy

Author

Pasquali, Sandro, Vallacchi, Viviana, Lalli, Luca, Collini, Paola, Barisella, Marta, Romagosa, Cleofe, Bague, Silvia, Coindre, Jean Michel, Dei Tos, Angelo Paolo, Palmerini, Emanuela, Quagliuolo, Vittorio, Martin-Broto, Javier, Lopez-Pousa, Antonio, Grignani, Giovanni, Blay, Jean-Yves, Beveridge, Robert Diaz, Casiraghi, Elena, Brich, Silvia, Renne, Salvatore Lorenzo, Bergamaschi, Laura, Vergani, Barbara, Sbaraglia, Marta, Casali, Paolo Giovanni, Rivoltini, Licia, Stacchiotti, Silvia, and Gronchi, Alessandro

Published
2024
Full Text
View/download PDF

4. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Loong, Herbert, Brunello, Antonella, Krieg, Andreas, Algulnik, Mark, Riedel, Richard, Okuno, Scott, Loggers, Elizabeth, Alcindor, Thierry, Ferraresi, Virginia, Serrano, César, Randall, R. Lor, Wilky, Breelyn, Ravi, Vinod, Gelderblom, Hans, Bhadri, Vivek, Stacchiotti, Silvia, Bauer, Sebastian, Wagner, Andrew J, van de Sande, Michiel, Bernthal, Nicholas M, López Pousa, Antonio, Razak, Albiruni Abdul, Italiano, Antoine, Ahmed, Mahbubl, Le Cesne, Axel, Tinoco, Gabriel, Boye, Kjetil, Martín-Broto, Javier, Palmerini, Emanuela, Tafuto, Salvatore, Pratap, Sarah, Powers, Benjamin C, Reichardt, Peter, Casado Herráez, Antonio, Rutkowski, Piotr, Tait, Christopher, Zarins, Fiona, Harrow, Brooke, Sharma, Maitreyi G, Ruiz-Soto, Rodrigo, Sherman, Matthew L, Blay, Jean-Yves, and Tap, William D

Published
2024
Full Text
View/download PDF

5. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A

Author

Martin-Broto, Javier, Martinez-Garcia, Jeronimo, Moura, David S., Redondo, Andres, Gutierrez, Antonio, Lopez-Pousa, Antonio, Martinez-Trufero, Javier, Sevilla, Isabel, Diaz-Beveridge, Roberto, Solis-Hernandez, Maria Pilar, Carnero, Amancio, Perez, Marco, Marcilla, David, Garcia-Foncillas, Jesus, Romero, Pablo, Fernandez-Jara, Javier, Lopez-Lopez, Daniel, Arribas, Ivan, and Hindi, Nadia

Published
2023
Full Text
View/download PDF

8. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial.

Author

Palmerini, Emanuela, Lopez Pousa, Antonio, Grignani, Giovanni, Redondo, Andres, Hindi, Nadia, Provenzano, Salvatore, Sebio, Ana, Lopez Martin, Jose Antonio, Valverde, Claudia, Martinez Trufero, Javier, Gutierrez, Antonio, de Alava, Enrique, Aparisi Gomez, Maria Pilar, D'Ambrosio, Lorenzo, Collini, Paola, Bazzocchi, Alberto, Moura, David S., Ibrahim, Toni, Stacchiotti, Silvia, and Broto, Javier Martin

Abstract

Background: Herein, we present the results of the phase 2 IMMUNOSARC study (NCT03277924), investigating sunitinib and nivolumab in adult patients with advanced bone sarcomas (BS). Methods: Progressing patients with a diagnosis of BS were eligible. Treatment was comprised of sunitinib (37.5 mg/day on days 1–14, 25 mg/day afterword) plus nivolumab (3 mg/kg every 2 weeks). Primary end point was progression‐free survival rate (PFSR) at 6 months based on central radiology review. Secondary end points were overall survival (OS), overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, and safety. Results: A total of 46 patients were screened, 40 patients entered the study, and 38 underwent central radiological review and were evaluable for primary end point. Median age was 47 years (range, 21–74). Histologies include 17 (43%) osteosarcoma, 14 chondrosarcoma (35%, 10 conventional, four dedifferentiated [DDCS]), eight (20%) Ewing sarcoma, and one (2%) undifferentiated pleomorphic sarcoma. The PFSR at 6 months was 42% (95% confidence interval [CI], 27–58). With a median follow‐up of 39.8 months (95% CI, 37.9–41.7), the median PFS and OS were 3.8 months (95% CI, 2.7–4.8) and 11.9 months (95% CI, 5.6–18.2). ORR by RECIST was 5%, with two of 38 partial responses (one of four DDCS and one of 17 osteosarcoma), 19 of 38 (50%) stable disease, and 17 of 38 (45%) progressions. Grade ≥3 adverse events were neutropenia (six of 40, 15%), anemia (5/40, hypertension (6/40, 15%), 12.5%), ALT/AST elevation (5/40, 12.5%), and pneumonitis (1/40, 2.5%). Seventeen percent of patients discontinued treatment due to toxicity, including a treatment‐related grade 5 pneumonitis Conclusion: The trial met its primary end point in the BS cohort with >15% of patients progression‐free at 6 months. However, the toxicity profile of this regimen was relevant. With a progression‐free survival of 42% at 6 months, this trial with nivolumab and sunitinib in 40 patients with advanced bone sarcoma met its primary end point. The response rate was high (25%) in patients with dedifferentiated chondrosarcoma (DDCS) and an international expansion phase 2 trial in DDCS is currently enrolling. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

9. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors

Author

Martin-Broto, Javier, Redondo, Andres, Moura, David S., Valverde, Claudia, Morales, Jose Manuel, Lopez-Pousa, Antonio, Martinez-Trufero, Javier, Gutierrez, Antonio, Díaz-Beveridge, Roberto, Luna, Pablo, Martinez-Marin, Virginia, Marcilla, David, Arribas, Ivan, Ledesma, Patricio, Lopez-Martin, Jose Antonio, Di Lernia, Davide, Zamora, Jorge, and Hindi, Nadia

Published
2022
Full Text
View/download PDF

12. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

Author

BABA-HAMED, Nabil, BABIN, Emmanuel, BERA, Guillaume, BETRIAN-LAGARDE, Sarah, BLOT, Emmanuel, BOMPAS, Emmanuelle, BOREL, Christian, BOUCHEKOUA, Mohamed, BOZEC LE MOAL, Laurence, BRUYAS, Amandine, CALAIS, Gilles, CARPIUC, Ioana, CHAPET, Sophie, CHATELLIER, Thierry, CHAUFFERT, Bruno, CHELI, Sandrine, CLATOT, Florian, COJOCARASU, Oana, CORNELLY, Alexandre, COUTTE, Alexandre, DALLOZ, Pierre, DARLOY, Franck, DELHOMMEAU, Melissa, DE RAUCOURT, Dominique, DEBELLEIX, Christophe, DEBOURDEAU, Philippe, DILLIES-LEGRAIN, Anne Françoise, DO, Pascal, DUBOS-ARVIS, Catherine, DUCOULOMBIER, Agnès, EL KOURI, Claude, FALKOWSKI, Sabrina, FERRAND, François-Regis, GATINEAU, Michel, GERVAIS, Radj, GRAS, Louis, GUILLET, Pierre, HASBINI, Ali, HENAULT, Stéphane, HERRERA GOMEZ, Ruth Gabriela, HUGUET, Florence, KAMINSKY, Marie Christine, LAGRANGE, Aurélie, LAVAU-DENES, Sandrine, LE CAER, Hervé, LE FOLL, Christine, LEFEBVRE, Gautier, LINOT, Benjamin, LOPEZ, Qian, LORTHOLARY, Alain, MATIAS, Margarida, MAYACHE-BADIS, Lamia, MINNE, Floriane, MOLLON, Delphine, NEIDHARDT, Eve Marie, PAVILLET, Julien, PEYRADE, Frédéric, POINTREAU, Yohann, RAMEE, Jean-François, RAUCHE, Camille, RICHARD, Sandrine, RIZZO, Claudia, ROLLAND, Frédéric, SCHLURMANN, Friderike, STEFANI, Laetitia, TASSY, Louis, TAZI, Youssef, THERY, Jean-Christophe, TORTI EL ZEIN, Florida, TOULLEC, Clémence, TOURANI, Jean-Marc, TOUSSAINT, Philippe, VANBOCKSTAEL, Julie, VAULEON, Elodie, VIRET, Frédéric, WALER, Sabine, ATZPODIEN, Jens, BEHRENS, Caecilia, BUSCH, Chia Jung, DIETZ, Andreas, FELDMANN, Georg, FIETKAU, Rainer, GRANIZKA, Thordis, GREWE, Jürgen, GUNTINAS-LICHINUS, Orlando, HADLER-MIKESCH, Kristina, HAHN, Dennis, INHESTERN, Johanna, KELLNER, Karolin, KLINGHAMMER, Konrad, KRONENBERGER, Roland, LUEDTKE-HECKENKAMP, Kerstin, OCHSENREITHER, Sebastian, OTREMBA, Burkhard, PEUKER, Caroline Anna, PIRLICH, Markus, ROTHMANN, Frank, TOMETTEN, Mareike, WOHLFARTH, Sabine, ZEBRALLA, Veit, ZIPFEL, Matthias, ADANSA KLEIN, Juan Carlos, ARRAZUBI, Virginia, CABALLERO DAROQUI, Javier, CASTELO, Beatriz, CIRAUQUI CIRAUQUI, Beatriz, CRUZ HERNANDEZ, Juan Jesus, GALLEGO, Oscar, IGLESIAS DOCAMPO, Lara Carmen, LOPEZ POUSA, Antonio, MARTINEZ DEL PRADO, Maria, MARTINEZ-TRUFERO, Javier, PASTOR BORGONON, Miguel, PEREZ RUIZ, Elisabeth, QUIROGA GARCIA, Vanesa, RUBIO CASADEVALL, Jordi, VAZQUEZ FERNANDEZ, Silvia, Guigay, Joël, Aupérin, Anne, Fayette, Jérôme, Saada-Bouzid, Esma, Lafond, Cédrik, Taberna, Miren, Geoffrois, Lionnel, Martin, Laurent, Capitain, Olivier, Cupissol, Didier, Castanie, Hélène, Vansteene, Damien, Schafhausen, Philippe, Johnson, Alison, Even, Caroline, Sire, Christian, Duplomb, Sophie, Evrard, Camille, Delord, Jean-Pierre, Laguerre, Brigitte, Zanetta, Sylvie, Chevassus-Clément, Cécile, Fraslin, Aldéric, Louat, Fanny, Sinigaglia, Laura, Keilholz, Ulrich, Bourhis, Jean, and Mesia, Ricard

Published
2021
Full Text
View/download PDF

15. Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma.

Author

Mondaza-Hernandez, José L., Hindi, Nadia, Fernandez-Serra, Antonio, Ramos, Rafael, Gonzalez-Cámpora, Ricardo, Gómez-Mateo, María Carmen, Martinez-Trufero, Javier, Lavernia, Javier, Lopez-Pousa, Antonio, Laínez, Nuria, Martinez-Garcia, Jeronimo, Valverde, Claudia, Vaz-Salgado, María Ángeles, Garcia-Plaza, Gabriel, Marin-Borrero, Isabel, Carrillo-Garcia, Jaime, Martin-Ruiz, Marta, Romero, Pablo, Gutierrez, Antonio, and López-Guerrero, Jose A.

Abstract

Background: Alveolar soft-part sarcoma (ASPS) is a rare tumor driven by the ASPSCR1-TFE3 fusion protein, with a propensity for metastasis. Prognostic factors remain poorly understood, and traditional chemotherapies are largely ineffective. Recent interest lies in immune checkpoint inhibitors (ICIs), yet predictive biomarkers for treatment response are lacking. Previous studies have shown promising results with ICIs in ASPS, indicating a need for further investigation into biomarkers associated with immune response. Objectives: To identify prognostic biomarkers in ASPS and to explore the role of immune-related markers, particularly L1CAM, in predicting patient outcomes. Design: A retrospective cohort study of 19 ASPS patients registered in the GEIS database. The study involved the collection of clinical and histopathological data, followed by an analysis of immune markers and gene expression profiles to identify potential prognostic indicators. Methods: Clinical and histopathological data were retrospectively collected from the GEIS-26 study cohort of 19 ASPS patients. Immunohistochemistry was performed to evaluate immune markers programmed death-1 ligand (PD-L1), programmed death-1, FAS, FASL, CD8, CD3, and CD4. An HTG ImmunOncology panel was conducted on formalin-fixed paraffin-embedded samples to explore gene expression. Effects of differentially expressed genes on survival were explored by Kaplan–Meier. Results: PD-L1 positivity was widely observed (63%) in tumors, and CD8+ lymphocytic infiltration was common. High CD8 density correlated with greater overall survival (OS) while not statistically significant. No associations were found for other immune markers. L1CAM was identified as differentially expressed in patients with low CD8 infiltration and correlated negatively with OS. Conclusion: High L1CAM expression correlated with poorer OS, highlighting its potential as a prognostic marker and therapeutic target in ASPS. Immunomodulatory interventions may hold promise, as evidenced by PD-L1 expression and CD8+ infiltration. Further research, including larger cohorts and international collaborations, is needed to validate these findings and explore therapeutic strategies targeting L1CAM in ASPS. Plain language summary: Understanding immune response in a rare cancer: exploring avenues for alveolar soft-part sarcoma Why was the study done? Alveolar soft-part sarcoma (ASPS) is a rare cancer with limited treatment options. Our study aimed to understand how the immune system responds to ASPS and explore potential treatments, as current therapies are often ineffective. What did the researchers do? We analyzed data from 19 ASPS patients to investigate immune response and potential treatment targets. We examined the expression of immune markers and genes related to immune response to identify factors influencing patient outcomes. What did the researchers find? We found that most tumors showed signs of an active immune response, with a protein called PD-L1 being present. We also noticed that many tumors had a type of immune cell called CD8+ lymphocytes. Although having more of these CD8+ cells seemed to be linked to better survival, this connection wasn't strong enough to be certain. We didn't find any clear links with other immune markers we looked at. However, we did find that a protein called L1CAM was more common in patients who had fewer CD8+ cells in their tumors, and this was linked to poorer overall survival. What do the findings mean? Our study sheds light on the immune response in ASPS and identifies potential targets for therapy. By understanding these mechanisms, we hope to pave the way for more effective treatments and improve outcomes for ASPS patients in the future. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial

Author

Martin-Broto, Javier, Cruz, Josefina, Penel, Nicolas, Le Cesne, Axel, Hindi, Nadia, Luna, Pablo, Moura, David S, Bernabeu, Daniel, de Alava, Enrique, Lopez-Guerrero, Jose Antonio, Dopazo, Joaquin, Peña-Chilet, Maria, Gutierrez, Antonio, Collini, Paola, Karanian, Marie, Redondo, Andres, Lopez-Pousa, Antonio, Grignani, Giovanni, Diaz-Martin, Juan, Marcilla, David, Fernandez-Serra, Antonio, Gonzalez-Aguilera, Cristina, Casali, Paolo G, Blay, Jean-Yves, and Stacchiotti, Silvia

Published
2020
Full Text
View/download PDF

17. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial

Author

Stacchiotti, Silvia, Ferrari, Stefano, Redondo, Andres, Hindi, Nadia, Palmerini, Emanuela, Vaz Salgado, Maria Angeles, Frezza, Anna Maria, Casali, Paolo Giovanni, Gutierrez, Antonio, Lopez-Pousa, Antonio, Grignani, Giovanni, Italiano, Antoine, LeCesne, Axel, Dumont, Sarah, Blay, Jean Yves, Penel, Nicolas, Bernabeu, Daniel, de Alava, Enrique, Karanian, Marie, Morosi, Carlo, Brich, Silvia, Dagrada, Gian Paolo, Vallacchi, Viviana, Castelli, Chiara, Brenca, Monica, Racanelli, Dominga, Maestro, Roberta, Collini, Paola, Cruz, Josefina, and Martin-Broto, Javier

Published
2019
Full Text
View/download PDF

18. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

Author

Judson, Ian, Morden, James P, Kilburn, Lucy, Leahy, Michael, Benson, Charlotte, Bhadri, Vivek, Campbell-Hewson, Quentin, Cubedo, Ricardo, Dangoor, Adam, Fox, Lisa, Hennig, Ivo, Jarman, Katy, Joubert, Warren, Kernaghan, Sarah, López Pousa, Antonio, McNeil, Catriona, Seddon, Beatrice, Snowdon, Claire, Tattersall, Martin, Toms, Christy, Martinez Trufero, Javier, and Bliss, Judith M

Published
2019
Full Text
View/download PDF

19. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)

Author

Gronchi, Alessandro, primary, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Martin Broto, Javier, additional, Lopez Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean-Yves, additional, Tendero, Oscar, additional, Diaz Beveridge, Robert, additional, Ferraresi, Virginia, additional, Lugowska, Iwona, additional, Pizzamiglio, Sara, additional, Verderio, Paolo, additional, Fontana, Valeria, additional, Donati, Davide Maria, additional, Palassini, Elena, additional, Sanfilippo, Roberta, additional, Bianchi, Giuseppe, additional, Bertuzzi, Alexia, additional, Morosi, Carlo, additional, Pasquali, Sandro, additional, Stacchiotti, Silvia, additional, Bagué, Silvia, additional, Coindre, Jean Michel, additional, Miceli, Rosalba, additional, Dei Tos, Angelo Paolo, additional, and Casali, Paolo Giovanni, additional

Published
2024
Full Text
View/download PDF

20. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial

Author

Martin-Broto, Javier, Stacchiotti, Silvia, Lopez-Pousa, Antonio, Redondo, Andres, Bernabeu, Daniel, de Alava, Enrique, Casali, Paolo G, Italiano, Antoine, Gutierrez, Antonio, Moura, David S, Peña-Chilet, Maria, Diaz-Martin, Juan, Biscuola, Michele, Taron, Miguel, Collini, Paola, Ranchere-Vince, Dominique, Garcia del Muro, Xavier, Grignani, Giovanni, Dumont, Sarah, Martinez-Trufero, Javier, Palmerini, Emanuela, Hindi, Nadia, Sebio, Ana, Dopazo, Joaquin, Dei Tos, Angelo Paolo, LeCesne, Axel, Blay, Jean-Yves, and Cruz, Josefina

Published
2019
Full Text
View/download PDF

21. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial

Author

Pasquali, Sandro, Colombo, Chiara, Pizzamiglio, Sara, Verderio, Paolo, Callegaro, Dario, Stacchiotti, Silvia, Martin Broto, Javier, Lopez-Pousa, Antonio, Ferrari, Stefano, Poveda, Andres, De Paoli, Antonino, Quagliuolo, Vittorio, Jurado, Josefina Cruz, Comandone, Alessandro, Grignani, Giovanni, De Sanctis, Rita, Palassini, Elena, Llomboart-Bosch, Antonio, Dei Tos, Angelo Paolo, Casali, Paolo G., Picci, Piero, and Gronchi, Alessandro

Published
2018
Full Text
View/download PDF

23. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma

Author

Sanfilippo, Roberta, primary, Hindi, Nadia, additional, Cruz Jurado, Josefina, additional, Blay, Jean-Yves, additional, Lopez-Pousa, Antonio, additional, Italiano, Antoine, additional, Alvarez, Rosa, additional, Gutierrez, Antonio, additional, Rincón-Perez, Inmaculada, additional, Sangalli, Claudia, additional, Pérez Aguiar, Jose Luis, additional, Romero, Jesús, additional, Morosi, Carlo, additional, Sunyach, Marie-Pierre, additional, Fabbroni, Chiara, additional, Romagosa, Cleofe, additional, Ranchere-Vince, Dominique, additional, Dei Tos, Angelo P., additional, Casali, Paolo G., additional, Martin-Broto, Javier, additional, and Gronchi, Alessandro, additional

Published
2023
Full Text
View/download PDF

24. Supplementary Table S4 from Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial

Author

Martin-Broto, Javier, primary, Lopez-Alvarez, Maria, primary, Moura, David S., primary, Ramos, Rafael, primary, Collini, Paola, primary, Romagosa, Cleofe, primary, Bagué, Silvia, primary, Renne, Salvatore L., primary, Barisella, Marta, primary, Velasco, Valerie, primary, Coindre, Jean-Michel, primary, Lopez-Lopez, Daniel, primary, Dopazo, Joaquin, primary, Gambarotti, Marco, primary, Braglia, Luca, primary, Merlo, Domenico Franco, primary, Palmerini, Emanuela, primary, Stacchiotti, Silvia, primary, Quagliuolo, Vittorio L., primary, Lopez-Pousa, Antonio, primary, Grignani, Giovanni, primary, Blay, Jean-Yves, primary, Brunello, Antonella, primary, Gutierrez, Antonio, primary, Valverde, Claudia, primary, Hindi, Nadia, primary, Dei Tos, Angelo Paolo, primary, Picci, Piero, primary, Casali, Paolo G., primary, and Gronchi, Alessandro, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Data from Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial

Author

Martin-Broto, Javier, primary, Lopez-Alvarez, Maria, primary, Moura, David S., primary, Ramos, Rafael, primary, Collini, Paola, primary, Romagosa, Cleofe, primary, Bagué, Silvia, primary, Renne, Salvatore L., primary, Barisella, Marta, primary, Velasco, Valerie, primary, Coindre, Jean-Michel, primary, Lopez-Lopez, Daniel, primary, Dopazo, Joaquin, primary, Gambarotti, Marco, primary, Braglia, Luca, primary, Merlo, Domenico Franco, primary, Palmerini, Emanuela, primary, Stacchiotti, Silvia, primary, Quagliuolo, Vittorio L., primary, Lopez-Pousa, Antonio, primary, Grignani, Giovanni, primary, Blay, Jean-Yves, primary, Brunello, Antonella, primary, Gutierrez, Antonio, primary, Valverde, Claudia, primary, Hindi, Nadia, primary, Dei Tos, Angelo Paolo, primary, Picci, Piero, primary, Casali, Paolo G., primary, and Gronchi, Alessandro, primary

Published
2023
Full Text
View/download PDF

26. Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Blay, Jean-Yves, Pápai, Zsuzsanna, Tolcher, Anthony W, Italiano, Antoine, Cupissol, Didier, López-Pousa, Antonio, Chawla, Sant P, Bompas, Emmanuelle, Babovic, Nada, Penel, Nicolas, Isambert, Nicolas, Staddon, Arthur P, Saâda-Bouzid, Esma, Santoro, Armando, Franke, Fabio A, Cohen, Patrick, Le-Guennec, Solenn, and Demetri, George D

Published
2015
Full Text
View/download PDF

33. Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)

Author

Rubió-Casadevall, Jordi, Martinez-Trufero, Javier, Garcia-Albeniz, Xabier, Calabuig, Silvia, Lopez-Pousa, Antonio, del Muro, Javier Garcia, Fra, Joaquin, Redondo, Andrés, Lainez, Nuria, Poveda, Andrés, Valverde, Claudia, De Juan, Ana, Sevilla, Isabel, Casado, Antonio, Andres, Raquel, Cruz, Josefina, Martin-Broto, Javier, Maurel, Joan, and the Spanish Group for Research on Sarcoma (GEIS)

Published
2015
Full Text
View/download PDF

34. CINSARC in high‐risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG‐STS 1001 study

Author

Frezza, Anna Maria, primary, Stacchiotti, Silvia, additional, Chibon, Frederic, additional, Coindre, Jean‐Michelle, additional, Italiano, Antoine, additional, Romagnosa, Cleofe, additional, Bagué, Silvia, additional, Dei Tos, Angelo Paolo, additional, Braglia, Luca, additional, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Broto, Javier Martin, additional, Lopez Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean‐Yves, additional, Beveridge, Robert Diaz, additional, Lugowska, Iwona, additional, Lesluyes, Tom, additional, Maestro, Roberta, additional, Merlo, Franco Domenico, additional, Casali, Paolo Giovanni, additional, and Gronchi, Alessandro, additional

Published
2022
Full Text
View/download PDF

35. Phase II trial of palbociclib in advanced sarcoma overexpressing CDK4 gene excluding dedifferentiated liposarcoma (DD LPS): A study from the Spanish Group for Research on Sarcoma (GEIS).

Author

Martin Broto, Javier, primary, Martinez Garcia, Jeronimo, additional, Moura, David Silva, additional, Redondo, Andres, additional, Gutierrez, Antonio, additional, Lopez-Pousa, Antonio, additional, Martinez-Trufero, Javier, additional, Sevilla, Isabel, additional, Diaz Beveridge, Robert, additional, Solis-Hernandez, Maria Pilar, additional, Carnero, Amancio, additional, Perez, Marco, additional, Marcilla, David, additional, Lopez-Martin, Jose A., additional, Casado Herraez, Antonio, additional, Alvarez Alvarez, Rosa Maria, additional, Cruz Jurado, Josefina, additional, Estival-Gonzalez, Anna, additional, Ledesma, Patricio, additional, and Hindi, Nadia, additional

Published
2022
Full Text
View/download PDF

36. Prognostic value of EZH2 expression for immunotherapy-based schemes in advanced soft-tissue sarcoma: A translational research from Spanish Group of Research on Sarcoma (GEIS).

Author

Moura, David Silva, primary, Zamora, Jorge, additional, Hindi, Nadia, additional, Lopez-Alvarez, Maria, additional, Lacerenza, Serena, additional, Grignani, Giovanni, additional, Martinez-Trufero, Javier, additional, Redondo, Andres, additional, Valverde Morales, Claudia Maria, additional, Stacchiotti, Silvia, additional, Lopez-Pousa, Antonio, additional, Gutierrez, Antonio, additional, Lopez-Martin, Jose A., additional, and Martin Broto, Javier, additional

Published
2022
Full Text
View/download PDF

37. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).

Author

Gronchi, Alessandro, primary, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Martin Broto, Javier, additional, Lopez-Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean-Yves, additional, Diaz Beveridge, Robert, additional, Ferraresi, Virginia, additional, Lugowska, Iwona, additional, Pizzamiglio, Sara, additional, Verderio, Paolo, additional, Fontana, Valeria, additional, Donati, Davide Maria, additional, Palassini, Elena, additional, Stacchiotti, Silvia, additional, Miceli, Rosalba, additional, Dei Tos, Angelo Paolo, additional, and Casali, Paolo Giovanni, additional

Published
2022
Full Text
View/download PDF

38. TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

Author

Adkins, Douglas, primary, Cheshuk, Valerii, additional, Peguero, Julio Antonio, additional, Park, John J., additional, Lopez-Pousa, Antonio, additional, Lybaert, Willem, additional, Brana, Irene, additional, Doger, Bernard, additional, and Triebel, Frederic, additional

Published
2022
Full Text
View/download PDF

43. Surgical implantation of CEB-01, novel drug delivery matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS)

Author

Gonzalez, José Antonio, primary, Sebio, Ana, additional, Cerdá, Paula, additional, Cano, Francesc, additional, Tornero, José Antonio, additional, Marti, Luc, additional, Barber, Imma, additional, Mora, Jaume, additional, Krauel, Lucas, additional, Asencio, José Manuel, additional, Alvarez, Rosa María, additional, Orbis, Juan Francisco, additional, Beveridge, Roberto Díaz, additional, and Lopez-Pousa, Antonio, additional

Published
2022
Full Text
View/download PDF

44. CINSARC in high‐risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG‐STS 1001 study.

Author

Frezza, Anna Maria, Stacchiotti, Silvia, Chibon, Frederic, Coindre, Jean‐Michelle, Italiano, Antoine, Romagnosa, Cleofe, Bagué, Silvia, Dei Tos, Angelo Paolo, Braglia, Luca, Palmerini, Emanuela, Quagliuolo, Vittorio, Broto, Javier Martin, Lopez Pousa, Antonio, Grignani, Giovanni, Brunello, Antonella, Blay, Jean‐Yves, Beveridge, Robert Diaz, Lugowska, Iwona, Lesluyes, Tom, and Maestro, Roberta

Subjects
NEOADJUVANT chemotherapy, SARCOMA, LOG-rank test
Abstract

Background: The Complexity INdex in SARComas (CINSARC) is a transcriptional signature derived from the expression of 67 genes involved in mitosis control and chromosome integrity. This study aims to assess CINSARC value of in an independent series of high‐risk patients with localized soft tissue sarcoma (STS) treated with preoperative chemotherapy within a prospective, randomized, phase III study (ISG‐STS 1001). Patients and Methods: Patients with available pre‐treatment samples, treated with 3 cycles of either standard (ST) preoperative or histotype‐tailored (HT) chemotherapy, were scored according to CINSARC (low‐risk, C1; high‐risk, C2). The 10‐year overall survival probability (pr‐OS) according to SARCULATOR was calculated, and patients were classified accordingly (low‐risk, Sarc‐LR, 10‐year pr‐OS>60%; high‐risk, Sarc‐HR, 10‐year pr‐OS<60%). Survival functions were estimated using the Kaplan–Meier method and compared using log‐rank test. Results: Eighty‐six patients were included, 30 C1 and 56 C2, 49 Sarc‐LR and 37 Sarc‐HR. A low level of agreement between CINSARC and SARCULATOR was observed (Cohen's Kappa = 0.174). The 5‐year relapse‐free survival in C1 and C2 were 0.57 and 0.55 (p = 0.481); 5‐year metastases‐free survival 0.63 and 0.64 (p = 0.740); 5‐year OS 0.80 and 0.72 (p = 0.460). The 5‐year OS in C1 treated with ST and HT chemotherapy was 0.84 and 0.76 (p = 0.251) respectively; in C2 treated it was 0.72 and 0.70 (p = 0.349). The 5‐year OS in Sarc‐LR treated with S and HT chemotherapy was 0.80 and 0.82 (p = 0.502) respectively; in Sarc‐HR it was 0.70 and 0.61 (p = 0.233). Conclusions: Our results, although constrained by the small size of the series, suggest that CINSARC has weak prognostic power in high‐risk, localized STS treated with neoadjuvant chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial

Author

Pasquali, Sandro, primary, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Martin‐Broto, Javier, additional, Lopez‐Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean‐Yves, additional, Tendero, Oscar, additional, Diaz‐Beveridge, Robert, additional, Ferraresi, Virginia, additional, Lugowska, Iwona, additional, Infante, Gabriele, additional, Braglia, Luca, additional, Merlo, Domenico Franco, additional, Fontana, Valeria, additional, Marchesi, Emanuela, additional, Donati, Davide Maria, additional, Palassini, Elena, additional, Bianchi, Giuseppe, additional, Marrari, Andrea, additional, Morosi, Carlo, additional, Stacchiotti, Silvia, additional, Bagué, Silvia, additional, Coindre, Jean Michel, additional, Dei Tos, Angelo Paolo, additional, Picci, Piero, additional, Bruzzi, Paolo, additional, Miceli, Rosalba, additional, Casali, Paolo Giovanni, additional, Gronchi, Alessandro, additional, Dani, Carla, additional, Villa, Chiara, additional, Messina, Antonella, additional, Rusi, Lorella, additional, Nuzzo, Anna Maria, additional, Nuzzo, Carmen, additional, De Paoli, Antonino, additional, Buonadonna, Angela, additional, Comandone, Alessandro, additional, Boglione, Antonella, additional, Livi, Lorenzo, additional, Greto, Daniela, additional, Riva, Nada, additional, Monti, Manuela, additional, Pennacchioli, Elisabetta, additional, De Pas, Tommaso, additional, Ippolito, Vincenzo, additional, Ledesma, Patrico, additional, Redondo, Andres, additional, Valverde, Claudia, additional, Bratos, Raquel, additional, Cruz, Josefina, additional, Martinez Trufero, Javier, additional, Cubedo, Ricardo, additional, Sevilla, Isabel, additional, Luna, Pablo, additional, Lopez, Rafael, additional, Sancho, Pilar, additional, Bally, Olivia, additional, Brahmi, Mehdi, additional, Ray‐Coquard, Isabelle, additional, Cassier, Philippe, additional, Marques, Nathalie, additional, Tassy, Luis, additional, Boudou‐Rouquette, Pascaline, additional, Tlemsani, Camille, additional, Alexandre, Jerome, additional, Goldwasser, Francois, additional, Bompas, Emmanuelle, additional, Rolland, Frederic, additional, Perrin, Christophe, additional, Talarmin, Marie, additional, Italiano, Antoine, additional, Toulmonde, Maud, additional, Laramas, Mathieu, additional, Bay, Jacques‐Olivier, additional, Dubray‐Longeras, Pascale, additional, and Rutkowski, Piotr, additional

Published
2021
Full Text
View/download PDF

46. Predictive value of MRP-1 in localized high-risk soft tissue sarcomas: a translational research associated to ISG-STS 1001 randomized phase III trial.

Author

Martín-Broto, Javier, primary, Lopez-Alvarez, Maria, additional, Moura, David S, additional, Ramos, Rafael, additional, Collini, Paola, additional, Romagosa, Cleofe, additional, Bagué, Silvia, additional, Renne, Salvatore L, additional, Barisella, Marta, additional, Vélasco, Valérie, additional, Coindre, Jean-Michel, additional, Lopez-Lopez, Daniel, additional, Dopazo, Joaquin, additional, Gambarotti, Marco, additional, Braglia, Luca, additional, Merlo, Domenico Franco, additional, Palmerini, Emanuela, additional, Stacchiotti, Silvia, additional, Quagliuolo, Vittorio L, additional, Lopez-Pousa, Antonio, additional, Grignani, Giovanni, additional, Blay, Jean-Yves, additional, Brunello, Antonella, additional, Gutierrez, Antonio, additional, Valverde, Claudia, additional, Hindi, Nadia, additional, Dei Tos, Angelo Paolo, additional, Picci, Piero, additional, Casali, Paolo G, additional, and Gronchi, Alessandro, additional

Published
2021
Full Text
View/download PDF

48. GEIS 39: Phase II trial of nabpaclitaxel for the treatment of patient with multiply relapsed/refractory desmoplastic small round cell tumor (DSRCT) and Ewing sarcoma (EwS).

Author

Mora, Jaume, primary, Suñol, Mariona, additional, Hindi, Nadia, additional, Castañeda, Alicia, additional, Redondo, Andrés, additional, Sirvent, Francisco José Bautista, additional, Diaz Beveridge, Robert, additional, Lopez-Pousa, Antonio, additional, Lopez-Martin, Jose A., additional, and Martin Broto, Javier, additional

Published
2021
Full Text
View/download PDF

50. First-in-human administration of CEB-01, a novel drug delivery implant matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS) after surgery: Preliminary safety and pharmacokinetics report.

Author

Gonzalez, José Antonio, primary, Sebio, Ana, additional, Cerdà, Paula, additional, Cano, Francesc, additional, Tornero, José Antonio, additional, Marti, Luc, additional, Mora, Jaume, additional, Krauel, Lucas, additional, and Lopez-Pousa, Antonio, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results